BEDMINSTER, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that the Vaccine Research Center (VRC) at
the National Institute of Allergy and Infectious Diseases (NIAID), part of the
National Institutes of Health, recently began its first human trial of a
vaccine to prevent Ebola infection utilizing the Biojector(R) 2000 (B-2000).
The B-2000 is a needle-free injection system that is powered by a compressed
gas system and is the only device being utilized in the study.
Earlier this year, Bioject had entered into a services and supply
subcontract with SAIC-Frederick, Inc., a subsidiary of Science Applications
International Corporation-Frederick (SAIC-Frederick) under its contract with
the National Cancer Institute, Frederick, where by Bioject will supply the
VRC/NIAID, with the non-exclusive right to utilize Bioject's B-2000 needle-
free injection systems in VRC-sponsored clinical trials for experimental
vaccines against HIV and Ebola. The HIV human clinical trials are currently
underway.
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
operations in Portland, Oregon, is an innovative developer and manufacturer of
needle-free drug delivery systems and vial adapter products. Needle-free
injection works by forcing medication at high speed through a tiny orifice
held against the skin. This creates a fine stream of high-pressure fluid
penetrating the skin and depositing medication in the tissue beneath. The
Company is focused on developing mutually beneficial agreements with leading
pharmaceutical, biotechnology, and veterinary companies.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995, including statements
regarding Bioject's expectations with respect to future revenues and earnings
and additional agreements with strategic partners. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the Company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Such risks, uncertainties and other factors include, without
limitation, the risk that the Company's products, including the cool.click(TM)
and the SeroJet(TM), will not be accepted by the market, the risk that the
Company will be unable to successfully develop and negotiate new strategic
relationships or maintain existing relationships, the risk that Bioject's
current or new strategic relationships will not develop into long-term revenue
producing relationships, the fact that Bioject's business has never been
profitable and may never be profitable, uncertainties related to Bioject's
dependence on the continued performance of strategic partners and technology,
uncertainties related to the time required for the Company to complete
research and development, obtain necessary clinical data and government
clearances, the risk that the Company may be unable to produce our products at
a unit cost necessary for the products to be competitive in the market and the
risk that the Company may be unable to comply with the extensive government
regulations applicable to Bioject's business. Readers of this press release
are referred to the Company's filings with the Securities and Exchange
Commission, including the Company's reports on Form 10-K and Forms 10-Q for
further discussions of factors that could affect the Company's business and
its future results. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. The Company
assumes no obligation to update forward-looking statements if conditions or
management's estimates or opinions should change.
For more information about Bioject, visit: http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Cecelia C. Heer, Investor Relations Manager
of Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5103,
or cheer@bioject.com
|
